Castle Biosciences, Inc. (CSTL)

16.78

-0.42

(-2.47%)

At close: May 9 at 4:00:01 PM EDT

17.25

+0.47

+(2.77%)

Pre-Market: 8:29:11 AM EDT

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 202

GlobeNewswire 3 days ago

CSTL
-2.47%
Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Castle Biosciences ( NASDAQ:CSTL ) First Quarter 2025 Results Key Financial Results Revenue: US$88.0m (up 21% from 1Q...

Simply Wall St. 5 days ago

CSTL
-2.47%
Castle Biosciences Celebrates Skin Cancer Awareness Month

At just 26 years old, Leah Adams heard the words no one wants to hear: malignant melanoma. In this powerful and emotional story, Leah shares how a routine skin check—prompted by her mother’s intuition—led to a life-altering diagnosis. As a runner and only child, Leah's journey through surgery, recovery, and her father’s parallel battle with stage 4 metastatic melanoma sheds light on how deeply this disease can impact families. Watch as Leah explains how the DecisionDx® Melanoma test helped guide

GlobeNewswire 5 days ago

CSTL
-2.47%
Q1 2025 Castle Biosciences Inc Earnings Call

Q1 2025 Castle Biosciences Inc Earnings Call

Thomson Reuters StreetEvents 5 days ago

CSTL
-2.47%
Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Castle Biosciences Inc (CSTL) reports a 21% revenue increase, driven by robust test volume growth, despite facing reimbursement and operational hurdles.

GuruFocus.com 6 days ago

CSTL
-2.47%
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of -150% and 9.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 days ago

CSTL
-2.47%
Castle Biosciences Reports First Quarter 2025 Results

Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, t

GlobeNewswire 6 days ago

CSTL
-2.47%
Castle Biosciences to Acquire Previse

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal he

GlobeNewswire 6 days ago

CSTL
-2.47%
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett’s Esophagus test via two posters at the

GlobeNewswire 9 days ago

CSTL
-2.47%
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in Cancer Diagnosis & Prognosis de

GlobeNewswire 11 days ago

CSTL
-2.47%
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Castle Biosciences celebrates an incredible milestone — the 200,000th order of the DecisionDx-Melanoma test! This milestone is so much more than a number: it represents 200,000 opportunities to provide clinicians and their patients with more accurate, more personalized insights that help guide their treatment plan decisions in melanoma care. With every test, we're empowering health care professionals to make more informed and more precise decisions that can fundamentally transform lives.Castle f

GlobeNewswire 14 days ago

CSTL
-2.47%
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research® (AACR) Annual Meeting 2025, being held April 25-30 in Chicago. "At Castle Biosciences, our commitment to advancing care for mela

GlobeNewswire 16 days ago

CSTL
-2.47%
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA li

GlobeNewswire 28 days ago

CSTL
-2.47%
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS) and The Gut Doctor PodcastLLC to promote esophageal cancer preventi

GlobeNewswire last month

CSTL
-2.47%
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. Castle was ranked 30th among 358 participating U.S. companies with 500-999 em

GlobeNewswire last month

CSTL
-2.47%
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression1,2 As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test result (Class 1A) were recur

GlobeNewswire last month

CSTL
-2.47%
Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

It is hard to get excited after looking at Castle Biosciences' (NASDAQ:CSTL) recent performance, when its stock has...

Simply Wall St. last month

CSTL
-2.47%
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovat

GlobeNewswire last month

CSTL
-2.47%
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predict

GlobeNewswire last month

CSTL
-2.47%
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

FRIENDSWOOD, Texas, March 07, 2025--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.

Business Wire 2 months ago

CSTL
-2.47%

Performance Overview

Return	CSTL	S&P 500 (^GSPC)
YTD	-37.02%	-3.77%
1-Year	-31.27%	+8.55%
3-Year	-12.44%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Castle Biosciences, Inc. (CSTL)

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Castle Biosciences Celebrates Skin Cancer Awareness Month

Q1 2025 Castle Biosciences Inc Earnings Call

Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences to Acquire Previse

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Performance Overview